Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $15.65 USD
Change Today +0.17 / 1.10%
Volume 2.5M
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Open
$15.71
Previous Close
$15.48
Day High
$16.49
Day Low
$15.27
52 Week High
03/18/15 - $37.04
52 Week Low
07/24/15 - $15.00
Market Cap
663.4M
Average Volume 10 Days
1.8M
EPS TTM
$-0.94
Shares Outstanding
42.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $966.6K
Chief Financial Officer and Vice President
Total Annual Compensation: $506.4K
Chief Operating Officer
Total Annual Compensation: $448.5K
Senior Vice President and General Counsel
Total Annual Compensation: $392.0K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $390.0K
Compensation as of Fiscal Year 2014.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Reports Consolidated Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Guidance for 2015

The Spectranetics Corporation reported consolidated unaudited financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $61,677,000 compared with $43,555,000 for the same period last year. Operating loss was $5,258,000 compared with $5,829,000 for the same period last year. Loss before taxes was $7,096,000 compared with $6,319,000 for the same period last year. Net loss was $7,216,000 or $0.17 basic and diluted per share compared with $5,299,000 $0.13 basic and diluted per share for the same period last year. Non-GAAP net loss was $9,238,000 or $0.22 basic and diluted per share compared with $2,461,000 $0.06 basic and diluted per share for the same period last year. For the six months, the company reported revenue of $119,099,000 compared with $83,169,000 for the same period last year. Operating loss was $30,483,000 compared with $11,347,000 for the same period last year. Loss before taxes was $34,254,000 compared with $11,833,000 for the same period last year. Net loss was $34,521,000 or $0.82 basic and diluted per share compared with $10,960,000 $0.26 basic and diluted per share for the same period last year. Non-GAAP net loss was $21,707,000 or $0.51 basic and diluted per share compared with $7,646,000 $0.18 basic and diluted per share for the same period last year. The company is revising its 2015 outlook, the company expected total revenue of $240 million to $250 million compared with previous guidance of $258.0 million. Net loss for 2015 is now projected to be within a range of $65 million to $69 million, or $1.53 to $1.62 per share, compared with $78 to $82 million, or $1.84 to $1.93 previously projected. Non-gaap net loss for 2015 is projected to be within a range of $41 million to $45 million, or $0.96 to $1.07 per share, and is essentially unchanged from previous guidance as a result of cost management initiatives implemented to offset the reduced projected revenue. Gross margin is expected to be within a range of 73.5% to 74.0%, approximately 100 basis points less than previously projected, primarily due to lower projected revenue associated with higher margin products. Research, development and other technology expenses are expected to be approximately 26.5% to 27.5% of revenue, revised from 27% to 28% previously projected.

The Spectranetics Corporation to Report Q2, 2015 Results on Jul 23, 2015

The Spectranetics Corporation announced that they will report Q2, 2015 results at 2:30 PM, Mountain Daylight on Jul 23, 2015

The Spectranetics Corporation, Q2 2015 Earnings Call, Jul 23, 2015

The Spectranetics Corporation, Q2 2015 Earnings Call, Jul 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $15.65 USD +0.17

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.40 USD -0.23
AtriCure Inc $23.24 USD -0.06
Cardiovascular Systems Inc $30.05 USD -0.17
Endologix Inc $14.20 USD -0.16
Vascular Solutions Inc $37.83 USD -0.30
View Industry Companies
 

Industry Analysis

SPNC

Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit www.spectranetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.